Citation Impact
Citing Papers
Biology of the Syndecans: A Family of Transmembrane Heparan Sulfate Proteoglycans
1992
More to “heparin” than anticoagulation
1994
Importance of specific amino acids in protein binding sites for heparin and heparan sulfate
1996
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Heparin-Protein Interactions
2002 Standout
Conversion of monomeric protein L to an obligate dimer by computational protein design
2001 StandoutNobel
Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms
2014
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection
2012
The heparanome and regulation of cell function: structures, functions and challenges
2008
Oligomer Formation By 3D Domain Swapping: A Model For Protein Assembly And Misassembly
1997
Characterization of the Binding of Different Conformational Forms of Plasminogen Activator Inhibitor-1 to Vitronectin
1997
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Mechanisms of Thrombus Formation
2008 Standout
Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model
2010
Structural and Functional Analysis of the Plasminogen Activator Inhibitor-1 Binding Motif in the Somatomedin B Domain of Vitronectin
1996
Receptor‐mediated endocytosis of plasminogen activators and activator/inhibitor complexes
1994
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Additivity in Effects of Vitronectin and Monoclonal Antibodies against α-Helix F of Plasminogen Activator Inhibitor-1 on Its Reactions with Target Proteinases
2004
Intact Vitronectin Induces Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinases-2 Expression and Enhanced Cellular Invasion by Melanoma Cells
1998
Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
2011 Standout
Folding of a model three-helix bundle protein: a thermodynamic and kinetic analysis 1 1Edited by A. R. Fersht
1999 StandoutNobel
A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response
2014
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain
2010
Endothelial cell regulation by transforming growth factor‐beta
1991
Plasminogen Activator Inhibitor-1 and Vitronectin Promote the Cellular Clearance of Thrombin by Low Density Lipoprotein Receptor-related Proteins 1 and 2
1996
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
2000 StandoutNobel
The Significance of Fibrin Binding by Plasminogen Activator Inhibitor 1 for the Mechanism of Tissue-type Plasminogen Activator-mediated Fibrinolysis
1995
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
2015 StandoutNobel
Multiple Oligomeric States of the Helicobacter pylori Vacuolating Toxin Demonstrated by Cryo-electron Microscopy
2002 StandoutNobel
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Inhibition of Amyloid Formation
2012
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
2012
A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation
2015 StandoutNobel
Protein folding and misfolding
2003 StandoutNature
Development, maintenance and disruption of the blood-brain barrier
2013 Standout
Post-exposure therapy with human butyrylcholinesterase following percutaneous VX challenge in guinea pigs
2011
PAI‐1 and atherothrombosis
2005
Maspin is an angiogenesis inhibitor
2000 Standout
An Antibody Fragment from a Phage Display Library Competes for Ligand Binding to the Low Density Lipoprotein Receptor Family and Inhibits Rhinovirus Infection
1995 StandoutNobel
Vitronectin decreases microvascular endothelial cell apoptosis
1998
Involvement of the [uPAR:uPA:PAI-1:LRP] Complex in Human Myogenic Cell Motility
2000
Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?
2015
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Inactivation of Plasminogen Activator Inhibitor-1 by Specific Proteolysis with Stromelysin-1 (MMP-3)
2000
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
A new class of membrane-bound chemokine with a CX3C motif
1997 StandoutNature
Heparin-induced conformational change and activation of mucus proteinase inhibitor
1992
Folding and Stability of a Primitive Protein
2005 StandoutNobel
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
2018 StandoutNobel
Plasminogen Activator Inhibitor-1 Contains a Cryptic High Affinity Binding Site for the Low Density Lipoprotein Receptor-related Protein
1998
Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial
2005 Standout
Oxime-assisted Acetylcholinesterase Catalytic Scavengers of Organophosphates That Resist Aging
2011 StandoutNobel
Pro-angiogenic Activities of CYR61 (CCN1) Mediated through Integrins αvβ3 and α6β1 in Human Umbilical Vein Endothelial Cells
2002 Standout
Specificity of Serine Proteinase/Serpin Complex Binding to Very‐Low‐Density Lipoprotein Receptor and α2‐Macroglobulin Receptor/Low‐Density‐Lipoprotein‐Receptor‐Related Protein
1997
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
The amyloid state and its association with protein misfolding diseases
2014 Standout
IgG Subclasses and Allotypes: From Structure to Effector Functions
2014 Standout
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders
2011 Standout
SARS-CoV-2 vaccines in development
2020 StandoutNature
Matrix Metalloproteinases
1999 Standout
Gene Transfer of Mutant Mouse Cholinesterase Provides High Lifetime Expression and Reduced Cocaine Responses with No Evident Toxicity
2013
Glycosaminoglycans and the regulation of blood coagulation
1993
Spontaneous Intracerebral Hemorrhage
2001 Standout
Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli.
1994
Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza
2008
Serpin Structure, Mechanism, and Function
2002 Standout
Plasmacytoid Dendritic Cells Delineate Immunogenicity of Influenza Vaccine Subtypes
2010
Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2
2020 Standout
Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
1994
Heparin protects cathepsin G against inhibition by protein proteinase inhibitors.
1994
Trousseau's syndrome: multiple definitions and multiple mechanisms
2007
Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate
1996
Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance.
1992
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Human Plasminogen Activator Inhibitor-1 (PAI-1) Deficiency: Characterization of a Large Kindred With a Null Mutation in the PAI-1 Gene
1997
Defective forebrain development in mice lacking gp330/megalin.
1996 Standout
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Imidazole Aldoximes Effective in Assisting Butyrylcholinesterase Catalysis of Organophosphate Detoxification
2014 StandoutNobel
Binding of urokinase-type plasminogen activator–plasminogen activator inhibitor-1 complex to the endocytosis receptors α2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor
1998
Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
1992
Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin
1994
Structures of Active and Latent PAI-1: A Possible Stabilizing Role for Chloride Ions
2000
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site
1991
MATRIX PROTEOGLYCANS: From Molecular Design to Cellular Function
1998 Standout
Quantitative mapping of glycoprotein micro‐heterogeneity and macro‐heterogeneity: an evaluation of mass spectrometry signal strengths using synthetic peptides and glycopeptides
2013
Functions of Cell Surface Heparan Sulfate Proteoglycans
1999 Standout
Role of Blood Clot Formation on Early Edema Development After Experimental Intracerebral Hemorrhage
1998
Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge
1998
THE CAVEOLAE MEMBRANE SYSTEM
1998 Standout
Role of Exosites 1 and 2 in Thrombin Reaction with Plasminogen Activator Inhibitor-1 in the Absence and Presence of Cofactors
1999
Chemical Glycoproteomics
2016 StandoutNobel
Endothelial Function and Dysfunction
2007 Standout
Works of Hartmut J. Ehrlich being referenced
Glycoproteomic characterization of butyrylcholinesterase from human plasma
2008
A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses
2009
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
2011
Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events
2002
Efficacy and physiological effects of human butyrylcholinesterase as a post-exposure therapy against percutaneous poisoning by VX in the guinea-pig
2010
A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
2008
Biochemical, molecular and preclinical characterization of a double‐virus‐reduced human butyrylcholinesterase preparation designed for clinical use
2010
Variation of anti‐Fas antibodies in different lots of intravenous immunoglobulin
2008
A close look at human IgG sialylation and subclass distribution after lectin fractionation
2009
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose priming
2012
A Whole Virus Pandemic Influenza H1N1 Vaccine Is Highly Immunogenic and Protective in Active Immunization and Passive Protection Mouse Models
2010
Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin
1991
P3‐248: Intravenous immunoglobulin (IVIg) Gammagard liquid contains anti‐RAGE IgG and sLRP
2009
Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma
2010
Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
1992
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
1990
Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
1991
Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator
1991
Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin.
1992